Explore Amgen Inc.'s latest 8-K report from May 23, 2025, detailing significant financial activities, including the issuance of 2.00% Senior Notes and stock information.
Explore Amgen Inc.'s latest 8-K report detailing common stock, senior notes, and financial strategies as of May 1, 2025. Key insights on debt management and market positioning.
Explore the current challenges in the biotech sector and discover resilient companies like Amgen, Gilead, Moderna, Illumina, and Vertex that present promising investment opportunities.
Explore Amgen's 2023 financial performance, highlighting revenue growth, net income decline, and litigation risks. A must-read for investors considering their positions.